Peter Birner
Overview
Explore the profile of Peter Birner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
4284
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gruber E, Oberhuber G, Schlederer M, Birner P, Jomrich G, Schoppmann S, et al.
Sci Rep
. 2024 Jul;
14(1):15988.
PMID: 38987552
AF1q associates with tumor progression and metastases upon WNT signaling. The downstream WNT target CD44 has demonstrated prognostic significance in gastric cancer (GC). This study evaluates the impact of AF1q...
2.
Gruber E, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, et al.
Cells
. 2020 Dec;
9(12).
PMID: 33371531
The authors wish to make the following change to their paper [...].
3.
Dinhof C, Pirker C, Kroiss P, Kirchhofer D, Gabler L, Gojo J, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33143299
The small-molecule E26 transformation-specific (ETS) factor inhibitor YK-4-279 was developed for therapy of ETS/EWS fusion-driven Ewing's sarcoma. Here we aimed to identify molecular factors underlying YK-4-279 responsiveness in ETS fusion-negative...
4.
Mungenast F, Meshcheryakova A, Beer A, Salzmann M, Tamandl D, Gruenberger T, et al.
Cancers (Basel)
. 2020 Oct;
12(11).
PMID: 33113874
The gut-associated lymphoid tissue represents an integral part of the immune system. Among the powerful players of the mucosa-associated lymphoid tissue are isolated lymphoid structures (ILSs), which as information centers,...
5.
Berghoff A, Kresl P, Rajky O, Widhalm G, Ricken G, Hainfellner J, et al.
Clin Neuropathol
. 2020 Aug;
39(6):256-262.
PMID: 32831157
Background: Properties of the inflammatory tumor microenvironment are associated with disease subtype, grade, and prognosis in various cancer entities. As immune-modulatory therapies are currently being explored in patients with meningeal...
6.
Gruber E, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, et al.
Cells
. 2019 Nov;
8(11).
PMID: 31671695
AF1q impairs survival in hematologic and solid malignancies. AF1q expression is associated with tumor progression, migration, and chemoresistance, and acts as a transcriptional co-activator in WNT and STAT signaling. This...
7.
Hu Z, Ding J, Ma Z, Sun R, Seoane J, Scott Shaffer J, et al.
Nat Genet
. 2019 Jun;
51(7):1113-1122.
PMID: 31209394
Both the timing and molecular determinants of metastasis are unknown, hindering treatment and prevention efforts. Here we characterize the evolutionary dynamics of this lethal process by analyzing exome-sequencing data from...
8.
Meshcheryakova A, Svoboda M, Jaritz M, Mungenast F, Salzmann M, Pils D, et al.
Comput Struct Biotechnol J
. 2019 May;
17:537-560.
PMID: 31049165
The sphingolipid and lysophosphatidate regulatory networks impact diverse mechanisms attributed to cancer cells and the tumor immune microenvironment. Deciphering the complexity demands implementation of a holistic approach combined with higher-resolution...
9.
Dorfer S, Kancz S, Birner P, Strasser K, Kirnbauer R, Petzelbauer P, et al.
Acta Derm Venereol
. 2019 Jan;
99(4):462-463.
PMID: 30653652
No abstract available.
10.
Schweiger T, Liebmann-Reindl S, Glueck O, Starlinger P, Laengle J, Birner P, et al.
J Thorac Dis
. 2019 Jan;
10(11):6147-6157.
PMID: 30622786
Background: Pulmonary metastasectomy is one of the cornerstones in the treatment of oligometastatic colorectal cancer (CRC). However, the selection of patients who benefit from a surgical resection is difficult. Mutational...